Industry Resources
Information is posted on this page as a service to our readers. Medications, treatments or procedures discussed in these resources should not be used by healthcare professionals without evaluating the patient, considering risks, contraindications and manufacturers’ product information. Resources may contain promotional content. APNA is not responsible for the content of external websites. Information provided here is not a replacement for a provider’s own due diligence.
Video: Intramuscular Injections
A video refresher on Long-Acting Injectable Antipsychotics for psychiatric professionals by Janssen Scientific Affairs.
Guide: Unseen and Unspoken
Resource about the importance of identifying, diagnosing, and treating bipolar I disorder
APNA Industry Sponsors
Abbvie
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
![]() |
Janssen Neuroscience Born from the legacy of our namesake, Dr. Paul Janssen, whose discoveries transformed the treatment and care for those with serious mental illness, Janssen Neuroscience works to heal minds and restore hope for people living with serious brain disorders. We collaborate with doctors, nurses, caregivers and people living with schizophrenia and other psychiatric and neurological disorders to improve health outcomes for those we serve and advance solutions that address critical needs. Learn more about these efforts at www.janssen.com/neuroscience. Follow us at www.twitter.com/JanssenUS. |
Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibrosis* and clinical development programs in multiple therapeutic areas. These areas include gene therapy for Parkinson’s disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.